EB101
/ Exom BioPharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 27, 2025
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
(clinicaltrials.gov)
- P3 | N=12 | Active, not recruiting | Sponsor: Abeona Therapeutics, Inc | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Sep 2025
Enrollment closed • Trial completion date • Trial primary completion date
1 to 1
Of
1
Go to page
1